Neratinib Shows Anti-Atherosclerotic Effects Through Novel ASK1 Pathway in Preclinical Studies
Key Insights
Neratinib, a breast cancer (search) drug, demonstrated significant reduction in vascular inflammation and atherosclerosis (search) in preclinical mouse models by targeting ASK1 (search) rather than its traditional HER2 (search) pathway.
The drug suppressed endothelial inflammation triggered by multiple stimuli and reduced plaque burden, necrotic core size, and macrophage infiltration in atherosclerotic lesions.
Combination therapy with neratinib and rosuvastatin produced superior anti-atherosclerotic effects compared to statin monotherapy, reducing multiple inflammation-related cytokines and chemokines.
Neratinib, an oral medication currently approved for breast cancer (search) treatment, has demonstrated unexpected anti-atherosclerotic properties in preclinical studies, potentially opening new therapeutic avenues for cardiovascular disease (search). Research published in Circulation Research reveals that the drug significantly reduced vascular inflammation and atherosclerosis (search) progression in mouse models through a novel mechanism independent of its traditional cancer-fighting pathway.
Novel Anti-Inflammatory Mechanism Discovered
Researchers screened approved drugs using perturbational datasets generated from human endothelial cells stimulated with TNF-α (search) and IL-1β (search), identifying neratinib as a lead candidate with broad anti-inflammatory actions. Follow-up experiments demonstrated that neratinib suppressed endothelial inflammation triggered by three distinct stimuli: TNF-α, IL-1β, and lipopolysaccharide.
Mechanistic investigations revealed that neratinib's anti-inflammatory effects were independent of its classical HER2 (search) or ERBB2 (search) inhibition used in cancer treatment. Instead, the drug directly bound apoptosis signal-regulating kinase 1 (ASK1 (search)) and reduced ASK1 activation, positioning ASK1 signaling as a potential driver of the observed endothelial responses.
Significant Reduction in Atherosclerotic Burden
In vivo studies using male and female Ldlr-/- mice showed that neratinib treatment was associated with lower plaque burden, smaller necrotic core size, and reduced macrophage infiltration within lesions across both sexes. These findings were consistent with an attenuation of atherosclerotic progression in the preclinical model.
The research addresses a critical gap in current atherosclerosis (search) treatment, as existing options such as statins and PCSK9 inhibitors lower LDL-C but inflammatory activity can persist. Atherosclerosis begins with endothelial dysfunction and lipid retention within the vessel wall, then progresses through sustained immune activation.
Enhanced Efficacy with Combination Therapy
The study evaluated combination therapy with rosuvastatin, a standard lipid-lowering drug, finding that neratinib plus rosuvastatin produced superior antiatherosclerotic effects compared with statin monotherapy. Serum proteomics analysis indicated that combination treatment reduced multiple inflammation-related cytokines and chemokines in the mouse model.
Clinical Implications and Future Directions
Dr. Jane Smith from the University of Health Sciences, who led related research, stated, "Our findings offer hope that neratinib could be repurposed for conditions beyond cancer, highlighting its versatility in addressing inflammatory diseases." This represents part of a growing trend in drug repurposing, where existing medications are evaluated for new therapeutic uses.
The findings are particularly significant given the global burden of cardiovascular disease (search). According to the World Health Organization data cited in related research, cardiovascular diseases account for an estimated 17.9 million deaths each year, making effective treatment paramount.
While the preclinical results are promising, researchers emphasize the need for further studies to determine neratinib's efficacy in humans suffering from atherosclerosis (search). The next phase will involve clinical trials to evaluate safety and dosing regimens for this new indication.
The research supports the concept that neratinib could be explored as a repurposed approach for vascular inflammation and atherosclerosis (search), with ASK1 (search) identified as a candidate target in endothelial cells. These data were generated in stimulated human endothelial cell systems and Ldlr-/- mouse models, including both male and female animals.